Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Ropivacain 5 Mgml Clonidine

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 3 (1)

Trial Status

Active Not Recruiting1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT06230081Not ApplicableActive Not RecruitingPrimary

Comparison Between Blocks or Not in Joint Arthroplasty

NCT02683239Phase 3CompletedPrimary

Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip

Showing all 2 trials

Research Network

Common Treatments

  • Ropivacain 5 Mgml Clonidine1
  • Fasinumab1

Active Sponsors

  • Teva Pharmaceutical Industries, Ltd.1
  • Regeneron Pharmaceuticals, Inc.1
  • Region Skane1

Top Investigators

Activity Timeline